Abstract:
In Graves’ disease the dosage of TSH antireceptor antibodies can be a helpful element in treatment management. When TSH antireceptor antibodies’ level is increased, it is not recommended to stop the treatment with anti-thyroidians of synthesis, because of the high risk of relapse. Persistence of a high level of anti-TPO antibodies may possibly subsequently result into hypothyroidism.
În cadrul bolii Graves-Basedow, dozarea a anticorpilor anti-receptori TSH poate constitui un element ajutător pentru dirijarea tratamentului: cînd titrul e ridicat, nu e cazul de a sista tratamentul fiind sporit riscul recidivelor. Persistenţa titrului înalt de anticorpi anti-TPO face posibilă instalarea unei ulterioare hipotiroidii.
